Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBITDA Margin (2018 - 2025)

BioNexus Gene Lab's EBITDA Margin history spans 8 years, with the latest figure at 27.74% for Q3 2025.

  • For Q3 2025, EBITDA Margin fell 1639.0% year-over-year to 27.74%; the TTM value through Sep 2025 reached 27.17%, down 2740.0%, while the annual FY2024 figure was 15.52%, 1413.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 27.74% at BioNexus Gene Lab, down from 11.02% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 30.6% in Q1 2021 and bottomed at 102.9% in Q3 2023.
  • The 5-year median for EBITDA Margin is 11.02% (2025), against an average of 11.48%.
  • The largest annual shift saw EBITDA Margin tumbled -204918bps in 2021 before it surged 9155bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 3.95% in 2021, then skyrocketed by 115bps to 8.5% in 2022, then surged by 123bps to 18.99% in 2023, then crashed by -322bps to 42.21% in 2024, then surged by 34bps to 27.74% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EBITDA Margin are 27.74% (Q3 2025), 11.02% (Q2 2025), and 25.79% (Q1 2025).